Company: BIAF
Filing Date: 2025-05-27
Form Type: 8-K
Source: 0001641172-25-012411
Chunk: 1

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-27
Form: 8-K
Item: Item 1.01
Chunk 1
---
 methods deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act. WallachBeth
will use commercially reasonable efforts in conducting such sales activities consistent with its normal trading and sales practices,
and applicable state and federal laws. The ATM Agreement will terminate on the sale of all of the shares of Common Stock subject to the
ATM Agreement and may also be terminated by the Company upon 10 days’ written notice to WallachBeth, as specified in the ATM Agreement
for any reason, or by WallachBeth upon 10 days’ written notice to the Company for any reason, or at any time under certain circumstances,
including but not limited to the occurrence of a material adverse change in the Company.

The
ATM Agreement provides that WallachBeth will be entitled to compensation for its services of 3.0% of the gross sales price of all shares
of Common Stock sold through WallachBeth under the ATM Agreement. The Company has no obligation to sell any shares under the ATM Agreement,
and may at any time suspend solicitation and offers under the ATM Agreement. The ATM Agreement contains customary representations, warranties
and agreements by the Company, indemnification obligations of the Company and WallachBeth, other obligations of the parties and termination
provisions. The Company will also reimburse WallachBeth for certain specified expenses in connection with entering into the ATM Agreement.

The
foregoing description of the ATM Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement,
a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

A
copy of the legal opinion and consent ofBlank Rome LLPrelating to the legality of the
shares of Common Stock that may be issued pursuant to the ATM Agreement is attached as Exhibit 5.1to
this Current Report on Form 8-K.

This
Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein,
nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such state or jurisdiction.